/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

INVENTIVA SA - ADR

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$4.05 -0.0096(-0.96%) IVA at 04 Dec 2025 04:35 PM Biotechnology
Lowest Today 3.99
Highest Today 4.17
Today’s Open 4.03
Prev. Close 4.18
52 Week High 7.98
52 Week Low 2.11
Day’s Range: Low 3.99 High 4.17
52-Week Range: Low 2.11 High 7.98
1 day return -
1 Week return -2.94
1 month return +2.1
3 month return -26.77
6 month return +20.67
1 year return +86.19
3 year return -
5 year return -67.19
10 year return -

Institutional Holdings

Yiheng Capital LLC 1.90

NEA Management Company, LLC 1.05

Bvf Inc 0.49

Commonwealth Equity Services Inc 0.04

UBS Group AG 0.02

Citadel Advisors Llc 0.02

Wealth Enhancement Advisory Services, LLC 0.01

Creative Planning Inc 0.01

Fidelity Nasdaq Composite Index 0.00

Morgan Stanley - Brokerage Accounts 0.00

Covestor Ltd 0.00

Atlantic Union Bankshares Corp 0.00

BNP Paribas Arbitrage, SA 0.00

Market Status

Strong Buy: 6

Buy: 0

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 557.31 M

PB Ratio 2.1025

PE Ratio 0.0

Enterprise Value 707.09 M

Total Assets 118.97 M

Volume 195168

Company Financials

Annual Revenue FY23:17477000 17.5M, FY22:12179000 12.2M, FY21:4194000 4.2M, FY20:372000 0.4M, FY19:6998000 7.0M

Annual Profit FY23:17500000 17.5M, FY22:12179000 12.2M, FY21:4194000 4.2M, FY20:372000 0.4M, FY19:6998000 7.0M

Annual Net worth FY23:-110426000 -110.4M, FY22:-54274000 -54.3M, FY21:-49636000 -49.6M, FY20:-31623000 -31.6M, FY19:-30221000 -30.2M

Quarterly Revenue Q2/2025:4454000 4.5M, Q1/2025:6464000 6.5M, Q3/2024:2734000 2.7M, Q2/2024:2734000 2.7M, Q1/2024:16541000 16.5M

Quarterly Profit Q2/2025:2750000 2.8M, Q1/2025:6990000 7.0M, Q3/2024:2734000 2.7M, Q2/2024:2734000 2.7M, Q1/2024:15983000 16.0M

Quarterly Net worth Q2/2025:-175882000 -175.9M, Q1/2025:-135183000 -135.2M, Q3/2024:-49029000 -49.0M, Q2/2024:-49029000 -49.0M, Q1/2024:-55157000 -55.2M

Fund house & investment objective

Company Information Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.

Organisation Biotechnology

Employees 84

Industry Biotechnology

CEO Mr. Andrew Obenshain

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow